UTHR
United Therapeutics Corporation
475.50$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 51.7% | 58.4% | 61.3% | 50.3% | 52.0% | 47.6% | 47.0% | 45.0% | 55.9% | 49.5% | 52.6% | 47.0% | |
| 21.1% | 38.1% | 44.0% | 24.5% | 19.7% | 18.9% | 16.0% | 17.3% | 15.9% | 16.9% | 23.0% | 19.8% | |
| 36.9% | 43.7% | 45.2% | 49.7% | 41.6% | 38.0% | 39.8% | 37.4% | 47.0% | 41.8% | 44.4% | 19.8% | |
| 8.6% | 8.8% | 9.2% | 10.3% | 5.2% | 3.9% | 3.4% | 3.8% | 3.6% | 3.9% | 3.8% | 4.4% | |
| 3.6% | 3.7% | 4.3% | 3.7% | 3.0% | 2.4% | 1.9% | 1.8% | 1.7% | 1.6% | 2.1% | 2.3% | |
| 25.4% | 22.7% | 21.0% | 19.0% | 20.6% | 18.9% | 15.9% | 15.1% | 14.3% | – | – | – | |
| 0.5% | 0.5% | 0.4% | 0.5% | 0.9% | 0.7% | 0.6% | 0.5% | 0.5% | 0.5% | 0.4% | 0.4% | |
| 1.0% | 0.8% | 1.0% | 1.1% | 4.1% | 3.3% | 2.8% | 0.3% | 0.3% | 1.1% | 1.1% | 1.5% | |
| 32.8% | 26.8% | 19.9% | 27.0% | 18.0% | 29.0% | 26.4% | 23.4% | 20.6% | 16.5% | 12.5% | 9.9% | |
| 26.8% | 20.2% | 14.3% | 15.4% | 8.1% | 11.8% | 7.0% | 5.9% | 5.7% | 11.2% | 10.0% | 7.1% | |
| 6.7% | 0.2% | – | 8.7% | – | 6.4% | – | – | – | 5.6% | 4.1% | 0.1% | |
| 0.4% | 0.3% | 0.3% | 0.3% | 0.7% | 0.3% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | |
| 0.0% | 0.0% | 0.0% | 8.7% | 7.4% | 15.3% | 17.3% | 15.5% | 13.2% | 4.2% | – | – | |
| 67.2% | 73.2% | 80.1% | 73.0% | 82.0% | 71.0% | 73.6% | 76.6% | 79.4% | 83.5% | 87.5% | 90.1% | |
| 56.7% | 78.7% | 104.6% | 98.8% | 101.0% | 85.0% | 83.2% | 83.5% | 83.4% | 84.1% | 98.1% | 108.6% | |
| 2.9% | 2.3% | 2.0% | 1.6% | 1.3% | 1.1% | 1.0% | 0.9% | 0.8% | 0.7% | 0.7% | 0.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.